Please ensure Javascript is enabled for purposes of website accessibility

Why Merck Stock Dropped Today

By Prosper Junior Bakiny - Apr 29, 2021 at 4:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors were not impressed with the company's latest quarterly update.

What happened?

Pharma giant Merck (MRK 0.24%) released a disappointing first-quarter 2021 earnings report on Thursday, and as a result, the company's stock took a bit of a dive today. The drugmaker's shares were down by 4.96% at the close of the day's trading session, after falling by as much as 5.5% earlier in the day.

So what

Merck's results were unimpressive in more ways than one. The company's sales came in at $12.1 billion, which more or less remained flat compared to the first quarter of the previous fiscal year. Meanwhile, Merck's adjusted earnings per share (EPS) was $1.40, representing a 7% decline compared to the year-ago period. Analysts tracking the company had predicted that on average, it would report revenue of $12.66 billion and adjusted EPS of $1.63.

Pills arranged in the form of a question mark.

Image source: Getty Images.

In other words, the pharma giant's results came in far short of analyst estimates -- on both the top and bottom lines. That's a recipe for disaster for any company. It is no wonder that investors sent Merck's stock tumbling today. Why did the healthcare company fail to deliver during the first quarter? Among other things, Merck blamed the continued fallout of the COVID-19 pandemic. According to the drugmaker, the negative impact of the outbreak on its top line during the first quarter amounted to roughly $600 million.

Now what

Merck's guidance for the full fiscal year 2021 was a bit more encouraging. On the top line, the company expects revenue between $51.8 billion and $53.8 billion. At the midpoint, this guidance would top the average analyst estimate of $52.5 billion. Merck also thinks it will record adjusted EPS between $6.48 to $6.68 during the current fiscal year, which at the midpoint is just slightly below the $6.57 adjusted EPS analysts are predicting.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.64 (0.24%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.